Is Palvella Therapeutics, Inc. (PVLA) a Buy, Sell, or Hold?
Palvella Therapeutics, Inc.
NASDAQ:PVLA
$149.68 USD
$3.65 (2.5%)
- Volume
- 241.78K
- Average Volume
- 258.14K
- Market Capitalization
- $1.77B
- P/E Ratio
- -35.89
- Dividend Yield
- 0.00%
- Price Target
- $220.00
- Year High
- $161.38
- Year Low
- $26.78
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $28.88
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Wesley H. Kaupinen |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | PVLA |
| CUSIP | 697947109 |
| CIK | 0001583648 |
| Web | https://palvellatx.com |
| Phone | 484 253 1461 |
| Currency | USD |
| Employees | 29 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 28.88 |
| Quick Ratio | 28.88 |
| Cash Ratio | 22.64 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.22 |
| Price / Cash Flow | -60.88 |
| Price / Book | 8.43 |
Price Target and Rating
| Average Stock Price Forecast | $220.00 |
| High Stock Price Forecast | $255.00 |
| Low Stock Price Forecast | $210.00 |
| Forecast Upside/Downside | -31.96% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.71 |
| Trailing P/E Ratio | -35.89 |
| PEG Ratio | -0.39 |
| P/E Growth | -0.39 |
| Net Income | $-41.72M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -56.87% |
| Return on Assets | -18.69% |
Financials Score
| AltmanZ Score | 31.88 |
| Piotroski Score | 2.00 |
| Working Capital | 254.12M |
| Total Assets | 263.76M |
| Ebit | -46.73M |
| Market Cap | 1.68B |
| Total Liabilities | 31.45M |
Poll Results
About Palvella Therapeutics, Inc. (NASDAQ:PVLA) Stock
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania. ...
2026-06-30 07:30:00
Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options
2026-06-29 07:30:00
FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
2026-06-27 12:11:54
4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average price of around $110.73 per share. This was a derivative transaction involving the exercise and immediate sale of options.
2026-06-22 07:30:00
FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted
2026-06-09 10:52:11
Palvella Therapeutics, Inc. (PVLA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Palvella Therapeutics: Qtorin Continues Making Progress, So I Remain Bullish
2026-06-05 07:30:00
Palvella Therapeutics is now a much more credible bet on QTORIN after their positive mLM data. They've also received some FDA feedback, which bodes well for their upcoming NDA submission. PVLA is now targeting a 2H2026 NDA submission for QTORIN rapamycin in mLM.
2026-06-03 07:30:00
Palvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malformations are serious, chronic, lifelong vascular malformations that can cause persistent leaking, bleeding, infection, functional impairment, and significant daily burden for patients and families QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and standard of care for the estimated more than 30,000 individuals with microcystic lymphatic malformations in the U.S. WAYNE, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced completion of its pre-New Drug Application (NDA) meeting with FDA for QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) in microcystic lymphatic malformations (microcystic LMs).
2026-06-02 07:30:00
WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026 at 8:40 a.m. ET.
Frequently Asked Questions
-
What is the current Palvella Therapeutics, Inc. (PVLA) stock price?
-
Palvella Therapeutics, Inc.(NASDAQ:PVLA) stock price is $149.68 in the last trading session. During the trading session, PVLA stock reached the peak price of $161.38 while $26.775 was the lowest point it dropped to. The percentage change in PVLA stock occurred in the recent session was 2.5% while the dollar amount for the price change in PVLA stock was $3.65.
-
PVLA's industry and sector of operation?
-
The NASDAQ listed PVLA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PVLA?
-
Kathleen Goin | Chief Operating Officer
Ashley Kline | Chief Commercial Officer
Bohan Wei | Vice President of Corporate Development & New Product Planning
Emily Cook | Senior Vice President of Clinical Operations
Sarah Foster | Senior Vice President of Human Resources -
How many employees does PVLA have?
-
Number of PVLA employees currently stands at 29. PVLA operates from 125 Strafford Avenue, Wayne, PA 19087, US.
-
Link for PVLA official website?
-
Official Website of PVLA is: https://palvellatx.com
-
How do I contact PVLA?
-
PVLA could be contacted at phone #484 253 1461 and can also be accessed through its website. PVLA operates from 125 Strafford Avenue, Wayne, PA 19087, US.
-
How many shares of PVLA are traded daily?
-
The average number of PVLA shares traded daily for last 3 months was 258.14K.
-
What is the market cap of PVLA currently?
-
The market value of PVLA currently stands at $1.77B with its latest stock price at $149.68